Daniel Wagner

Bexorg is a privately held techbio company with the first-ever full tech stack platform to support CNS drug discovery and development in the human brain in a way that has not been possible before.  Our proprietary whole-brain perfusion technology can be used to study brain connectivity, circuit function, and disease processes, with the aim to identify novel targets, biomarkers, and effectiveness of therapeutics for neurological disorders before going into the clinic. Our proprietary BrainEx platform generates high-fidelity human brain molecular datasets that drive our XO Digital application, a machine learning and AI-centered engine for drug discovery and development. In collaboration with the NIH, Bexorg’s founders have been at the forefront of bioethics in post-mortem human brain scientific research, and we have an independent board comprised of bioethics leaders to ensure our operations maintain the highest standards. Bexorg is strategically partnering with leading neuroscience companies to integrate its platform into CNS clinical development programs, as well as advancing in-house neurodegeneration assets.

Precision Diagnostics for Personalized Cancer Therapy

Revalia Bio is a seed series start-up spun out of Yale with 20M funding, 30M government contracts, and 40M research grants. Revalia Bio is seeking to revolutionize biomedical innovation by creating the worlds first integrated human data stack.

Enrich Biosystems develops a highly integrated microfluidics-free high-throughput cell imaging/analysis/capture platform to accelerate cell-based biology and therapy discovery, precision medicine, and many other critical life science applications. Its bench-top instrument enables short and long-term studies of interactions between living cells. The need for these studies is extensive, including cancer, immunology, and stem cells, in activities ranging from pure research to human clinical therapies. Enrich technology was invented by scientists who were struggling with the complex workflow of monitoring cell/cell interactions using microfluidics-based tools. It is straightforward to use, providing a low-risk, affordable tool for any academic and industrial labs.

Intus Bio is using its proprietary high-resolution, high-throughput assay and analysis technology to identify bacteria and deliver answers about the microbiome, with unprecedented detail, accuracy and scale. The company is powering groundbreaking research, discovery and services with clients and partners across the global pharmaceutical, diagnostic, and testing industries; is active in health, agricultural, and environmental fields; and continues to develop new and innovative partnerships, technologies, and applications.

Manifest was founded by a group of leading experts in computational neuroimaging and psychiatry at Yale Universitys School of Medicine. Our goal is to transform therapeutic development, diagnosis and treatment for CNS disorders. The company is advancing the worlds first AI-powered computational neuroimaging system that quantifies neural and symptom data to create and choose the right therapy for the right patient at the right time.

RIGImmune is a biopharmaceutical research company focused on the development of innovative RNA therapeutics to prevent or treat serious respiratory diseases with high unmet clinical needs. The company was co-founded by the prominent scientists Drs. Akiko Iwasaki and Anna Pyle from Yale University to advance the development of a novel class of oligonucleotides called stem-loop RNA therapeutics or “SLRs,” which were discovered in Dr. Pyle’s laboratory. To effectively deliver these RNA compounds without requiring lipid nanoparticle encapsulation, RIGImmune internally developed a proprietary nano-emulsion delivery technology platform named NEED™ and collaborates with SubIntro, which was co-founded by the prominent research scientists and successful respiratory drug and formulation developers, Drs. Garth Rapeport, Kazuhiro Ito, and Jag Shur. RIGImmune’s lead products aim to enhance the innate immune response against viral respiratory diseases, and treat cystic fibrosis, respectively. More information is available at: rigimmune.com.

At Alphina Therapeutics we are working to fulfill the promise of precision oncology — higher response rates for more patients. Our approach combines two cutting-edge scientific breakthroughs: First, our drug candidates use antibody-drug conjugate (ADC) technology to deliver potent NAMPT inhibitor payloads directly to the tumor. By disrupting cancer’s energy supply, these next-generation payloads are designed to kill both dividing and non-dividing tumor cells. Importantly, our therapies can be effective even when other ADCs, including Topo1-based treatments, no longer work. Second, we have developed a proprietary test that identifies the patients most likely to benefit from NAMPT inhibitors. Our goal is simple: match the right treatment with the right patient to achieve superior outcomes. Unlike most targeted treatments that help relatively few patients, ours could benefit more than 450,000 people each year in the U.S. alone. Our mission is to apply these breakthroughs to deliver smarter, more effective cancer therapies to the patients who urgently need them.

Purpose-built for organizations conducting clinical trials and observational studies, we leverage our AI-powered patient-matching platform and clinical expertise to optimize feasibility and speed up patient identification by extracting structured and unstructured data from electronic medical records (EMRs) that captures three times more trial criteria. Why: We believe sites are vital to the success of clinical trials. Empowering them to find the right patient for the right research at the right time is the focus of everything we do. What: We leverage our best-in-class technology and data expertise to detect more protocol-eligible candidates than traditional methods, so that site teams can focus on the parts of the job they actually love. How: We deliver an AI-powered software platform and support from clinical experts that enables our customers to find and match patients to available clinical research. With unbelievably fast and highly-accurate data extraction from electronic medical records (EMRs) we can capture three times more trial criteria - making trial participation more accessible and efficient.

TastesNatural™ A Taste Technology Company We are a food ingredient company dedicated to organic, all-natural ingredients that improve the taste of the food, beverage, nutraceuticals, and pharmaceuticals that we all consume. The company has a proprietary, patent-pending process to extract active ingredients from all-natural botanical feedstock. Our bitter blockers are sustainable, plant-based, and have a track record of proven success across a variety of industries and markets. The Company is focused on B2B, selling directly through customer success staff and indirectly through select resellers. We believe great tasting and truly healthy products are possible without compromise. TastesNatural™ focuses on the client’s end-consumer and their ever-changing needs first. We utilize our proprietary process to develop unique taste technologies in conjunction with flavors from around the world to overcome the barriers that prevent great taste. We Make Healthy Taste Good™ - head to our website to request samples and learn more about our forward-thinking products.

Bringing the Power of Proteomics to Every Lab Bench! ProteoWise is revolutionizing multiplex protein analysis with the Hyperblot System. The Problem: Proteomics is hard to do at the lab bench. Traditional western blot analysis is cumbersome, consumes a lot of sample and yields very little data per run. This bottleneck makes proteomic hypothesis investigation very difficult. The Solution: ProteoWise has developed a product with an immortalized membrane that captures and covalently binds protein, allowing hundreds of targets to be rapidly analyzed on the same sample - today, tomorrow, next year – this allows focused, limitless proteomic interrogation for the first time.

Simcha Therapeutics is a clinical-stage immunobiology company pioneering the development of first-in-class engineered cytokine therapeutics with transformational promise for patients. The company is built on a foundation of scientific rigor to overcome biological challenges in clinically translatable pathways, exemplified by the first decoy-resistant interleukin-18 (IL-18). By unlocking the potential of IL-18, Simcha is developing its lead program (ST-067) as monotherapy and in combination with potentially several other anticancer agents. ST-067 is currently being studied in a Phase 1/2 clinical trial, in patients with solid tumors and who have progressed on other immunotherapeutic agents. Beyond IL-18, the company’s underlying approach to immune-biology and cytokine engineering has broader potential to support disease-modifying therapeutic options for a range of significant diseases.

Halda is inventing novel precision medicines for oncology. Specifically, we are developing RIPTAC™ therapeutics, a new drug modality for the treatment of cancer. Founded by world renowned Yale scientist, Professor Craig Crews, Halda invented RIPTAC therapeutics as an innovative cancer treatment approach that does not rely on traditional oncogenic disease drivers to target cancer. This powerful technology is designed to overcome the known bypass mechanisms of drug resistance, a common limitation of today’s precision cancer medicines. Using a novel ‘hold and kill’ mechanism, RIPTAC therapeutics target cancer cells selectively by bringing two proteins together in a tightly regulated manner, causing the loss of an essential function for cell survival and subsequent cancer cell death. We have built a pipeline of RIPTAC therapeutics for major cancer types, uniquely addressing the unmet needs of drug resistant cancer patients, and we will continue to invent new medicines using our proprietary platform technology. We are a bold company where collaboration, passion, and creativity thrive, all of which allows us to push the boundaries of drug discovery to identify better solutions. Halda is proud to be a New Haven, CT based biotech, located with headquarters and state-of-the-art labs in Science Park.

Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). Rallybio’s pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Rallybio is headquartered in New Haven, Connecticut.

Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. Azitra’s lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. ATR-04, Azitras additional clinical program, utilizes another engineered strain of S. epidermidis for the treatment of EGFR inhibitor ("EGFRi") associated skin toxicity. The ATR-12 and ATR-04 programs were developed from Azitras proprietary platform of engineered proteins and topical live biotherapeutic products that includes a microbial library comprised of approximately 1,500 bacterial strains. The Company was founded in 2014 by scientists from Yale University and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its programs in atopic dermatitis and targeted orphan indications. For more information visit www.azitrainc.com.

Bexorg is a privately held techbio company with the first-ever full tech stack platform to support CNS drug discovery and development in the human brain in a way that has not been possible before.  Our proprietary whole-brain perfusion technology can be used to study brain connectivity, circuit function, and disease processes, with the aim to identify novel targets, biomarkers, and effectiveness of therapeutics for neurological disorders before going into the clinic. Our proprietary BrainEx platform generates high-fidelity human brain molecular datasets that drive our XO Digital application, a machine learning and AI-centered engine for drug discovery and development. In collaboration with the NIH, Bexorg’s founders have been at the forefront of bioethics in post-mortem human brain scientific research, and we have an independent board comprised of bioethics leaders to ensure our operations maintain the highest standards. Bexorg is strategically partnering with leading neuroscience companies to integrate its platform into CNS clinical development programs, as well as advancing in-house neurodegeneration assets.

Precision Diagnostics for Personalized Cancer Therapy

Revalia Bio is a seed series start-up spun out of Yale with 20M funding, 30M government contracts, and 40M research grants. Revalia Bio is seeking to revolutionize biomedical innovation by creating the worlds first integrated human data stack.

Enrich Biosystems develops a highly integrated microfluidics-free high-throughput cell imaging/analysis/capture platform to accelerate cell-based biology and therapy discovery, precision medicine, and many other critical life science applications. Its bench-top instrument enables short and long-term studies of interactions between living cells. The need for these studies is extensive, including cancer, immunology, and stem cells, in activities ranging from pure research to human clinical therapies. Enrich technology was invented by scientists who were struggling with the complex workflow of monitoring cell/cell interactions using microfluidics-based tools. It is straightforward to use, providing a low-risk, affordable tool for any academic and industrial labs.

Intus Bio is using its proprietary high-resolution, high-throughput assay and analysis technology to identify bacteria and deliver answers about the microbiome, with unprecedented detail, accuracy and scale. The company is powering groundbreaking research, discovery and services with clients and partners across the global pharmaceutical, diagnostic, and testing industries; is active in health, agricultural, and environmental fields; and continues to develop new and innovative partnerships, technologies, and applications.